Skip to content

Evommune, Inc.

EVMN

CIK 0002044725

← back to feed
Revenue (TTM)
$13M
+85.7% YoY Q1 May 2026
Net Income (TTM)
−$64.62M
−3.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$28.66
+75.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-529.5%
Q1 May 2026
Net Margin
-497.1%
Q1 May 2026
Free Cash Flow (TTM)
−$76.68M
Q1 May 2026
Cash
$48.32M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
36.02M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings